Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arbormentis
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Arbormentis had a preclinical program focused on novel psilocybin and derivatives to promote neural plasticity for CNS disease; a licensing agreement granted Relmada Therapeutics rights to the program for ex-Asia regions[1][6][9]. No clinical data reported as of the licensing (mid-2021).
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small moleculePsychedelic derivative
- Industry
- Biotech
02
Partnerships
Relmada Therapeutics (licensed development and commercialization rights ex-Asia)[1]
Beyond the preview
Go deeper on Arbormentis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arbormentis.